FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061211083> ?p ?o ?g. }

• W2061211083 endingPage "2835" @default.
• W2061211083 startingPage "2828" @default.
• W2061211083 abstract "Background. A Phase I/II randomized dose-seeking trial was performed to document the severity, time course, and significance of white matter changes seen on serial imaging scans (magnetic resonance imaging, computed tomography) associated with bis-chlorethyl nitrosourea (BCNU) and hyperfractionated cranial irradiation. Methods. Long term survivors (⩾ 18 months) were identified from a prospective randomized dose-escalation Phase I/II trial designed to evaluate twice-daily radiotherapy for supratentorial high grade malignant gliomas. All scans were reviewed by a neuroradiologist who had no information about the prescribed dose and fractionaction. In the trial, patients were assigned to receive 64.8 Gy, 72.0 Gy, 76.8 Gy, or 81.4 Gy (all fractionated as 1.2 Gy twice a day [bid]), or 48.0 Gy or 54.4 Gy (both in 1.6-Gy bid fractions). Bis-chlorethyl nitrosourea was administered every 8 weeks for 1 year. Of 747 randomized patients, 177 had analyzable scans. The scans reviewed were those acquired preoperatively, immediately postoperatively, 3, 6, 12, and 18 months after radiotherapy. Radiographic endpoints included no white matter change (Grade 0), minimal patchy white matter foci (Grade 1), start of confluence of white matter disease (Grade 2), large confluent areas (Grade 3), confluence with cortical/subcortical involvement (Grade 4), leukoencephalopathy (Grade 5), and possible necrosis (Grade 6) according to the classification of F. Fazekas et al. 9The effects were scored relative to the baseline preoperative scans. The dose pairs of 48 Gy and 54.4 Gy, 64.8 Gy and 72 Gy, and 76.8 Gy and 81.4 Gy were grouped together for analysis (low, intermediate, and high dose, respectively). Toxicity was analyzed in three ways: Grade 2 or worse, Grade 3 or worse, and Grade 6. Results. Grade 2 or worse changes were observed in 26.6, 27.6, and 40.4% of patients in the low, intermediate, and high dose groups, respectively. Grade 3 or worse changes were observed in 8.3, 20.0, and 36.5% of patients in the low, intermediate, and high dose groups, respectively. Grade 6 changes were observed in 1.6, 4.6, and 19.2% of patients in the low, intermediate, and high dose groups, respectively. No statistically significant differences were observed among treatment groups when toxicity was evaluated as Grade 2 or worse. For toxicity of Grade 3 or worse, an chi-square test revealed P values of 0.04 (low vs. intermediate dose), 0.09 (intermediate vs. high dose), and 0.0005 (low vs. high dose). With the endpoint of possible necrosis (Grade 6), P values were 0.21 (low vs. intermediate dose), 0.05 (intermediate vs. high dose), and 0.003 (low vs. high dose). The median time to radiographic appearance of an effect (15 months) was not influenced by total dose or fraction size. Conclusions. A well described toxicity scale for white matter injury was applied successfully to patients with malignant glioma treated with definitive irradiation. Severe white matter changes continued to increase significantly as the total dose of hyperfractionated cranial irradiation was escalated. The time to onset of the white matter abnormalities appeared to be independent of dose. An ongoing Radiation Therapy Oncology Group study will allow correlation of white matter injury with prospective neuropsychometric testing." @default.
• W2061211083 created "2016-06-24" @default.
• W2061211083 creator A5011571510 @default.
• W2061211083 creator A5013549286 @default.
• W2061211083 creator A5026088869 @default.
• W2061211083 creator A5030653008 @default.
• W2061211083 creator A5035978215 @default.
• W2061211083 creator A5068710491 @default.
• W2061211083 creator A5080119679 @default.
• W2061211083 creator A5081900423 @default.
• W2061211083 date "1994-11-15" @default.
• W2061211083 modified "2023-10-13" @default.
• W2061211083 title "White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (radiation therapy oncology group 83-02)" @default.
• W2061211083 cites W1971747664 @default.
• W2061211083 cites W1972125775 @default.
• W2061211083 cites W1990537396 @default.
• W2061211083 cites W1994118653 @default.
• W2061211083 cites W1996177628 @default.
• W2061211083 cites W2006774085 @default.
• W2061211083 cites W2031230850 @default.
• W2061211083 cites W2033128037 @default.
• W2061211083 cites W2034786584 @default.
• W2061211083 cites W2036560693 @default.
• W2061211083 cites W2077668530 @default.
• W2061211083 cites W2111695740 @default.
• W2061211083 cites W2152892024 @default.
• W2061211083 cites W2164877855 @default.
• W2061211083 cites W2168161253 @default.
• W2061211083 doi "https://doi.org/10.1002/1097-0142(19941115)74:10<2828::aid-cncr2820741014>3.0.co;2-k" @default.
• W2061211083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7954244" @default.
• W2061211083 hasPublicationYear "1994" @default.
• W2061211083 type Work @default.
• W2061211083 sameAs 2061211083 @default.
• W2061211083 citedByCount "124" @default.
• W2061211083 countsByYear W20612110832012 @default.
• W2061211083 countsByYear W20612110832013 @default.
• W2061211083 countsByYear W20612110832014 @default.
• W2061211083 countsByYear W20612110832015 @default.
• W2061211083 countsByYear W20612110832016 @default.
• W2061211083 countsByYear W20612110832017 @default.
• W2061211083 countsByYear W20612110832018 @default.
• W2061211083 countsByYear W20612110832019 @default.
• W2061211083 countsByYear W20612110832020 @default.
• W2061211083 countsByYear W20612110832021 @default.
• W2061211083 countsByYear W20612110832022 @default.
• W2061211083 countsByYear W20612110832023 @default.
• W2061211083 crossrefType "journal-article" @default.
• W2061211083 hasAuthorship W2061211083A5011571510 @default.
• W2061211083 hasAuthorship W2061211083A5013549286 @default.
• W2061211083 hasAuthorship W2061211083A5026088869 @default.
• W2061211083 hasAuthorship W2061211083A5030653008 @default.
• W2061211083 hasAuthorship W2061211083A5035978215 @default.
• W2061211083 hasAuthorship W2061211083A5068710491 @default.
• W2061211083 hasAuthorship W2061211083A5080119679 @default.
• W2061211083 hasAuthorship W2061211083A5081900423 @default.
• W2061211083 hasBestOaLocation W20612110831 @default.
• W2061211083 hasConcept C126838900 @default.
• W2061211083 hasConcept C141071460 @default.
• W2061211083 hasConcept C143409427 @default.
• W2061211083 hasConcept C168563851 @default.
• W2061211083 hasConcept C2778227246 @default.
• W2061211083 hasConcept C2781192897 @default.
• W2061211083 hasConcept C2989005 @default.
• W2061211083 hasConcept C502942594 @default.
• W2061211083 hasConcept C509974204 @default.
• W2061211083 hasConcept C71924100 @default.
• W2061211083 hasConceptScore W2061211083C126838900 @default.
• W2061211083 hasConceptScore W2061211083C141071460 @default.
• W2061211083 hasConceptScore W2061211083C143409427 @default.
• W2061211083 hasConceptScore W2061211083C168563851 @default.
• W2061211083 hasConceptScore W2061211083C2778227246 @default.
• W2061211083 hasConceptScore W2061211083C2781192897 @default.
• W2061211083 hasConceptScore W2061211083C2989005 @default.
• W2061211083 hasConceptScore W2061211083C502942594 @default.
• W2061211083 hasConceptScore W2061211083C509974204 @default.
• W2061211083 hasConceptScore W2061211083C71924100 @default.
• W2061211083 hasIssue "10" @default.
• W2061211083 hasLocation W20612110831 @default.
• W2061211083 hasLocation W20612110832 @default.
• W2061211083 hasOpenAccess W2061211083 @default.
• W2061211083 hasPrimaryLocation W20612110831 @default.
• W2061211083 hasRelatedWork W2022944059 @default.
• W2061211083 hasRelatedWork W2125247442 @default.
• W2061211083 hasRelatedWork W2384708512 @default.
• W2061211083 hasRelatedWork W2507295142 @default.
• W2061211083 hasRelatedWork W2729161207 @default.
• W2061211083 hasRelatedWork W2810702825 @default.
• W2061211083 hasRelatedWork W3159250744 @default.
• W2061211083 hasRelatedWork W4256514411 @default.
• W2061211083 hasRelatedWork W4292236216 @default.
• W2061211083 hasRelatedWork W4317687413 @default.
• W2061211083 hasVolume "74" @default.
• W2061211083 isParatext "false" @default.
• W2061211083 isRetracted "false" @default.
• W2061211083 magId "2061211083" @default.
• W2061211083 workType "article" @default.